{
    "clinical_study": {
        "@rank": "60389", 
        "arm_group": {
            "arm_group_label": "chemotherapy/radiation", 
            "arm_group_type": "Experimental", 
            "description": "cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation."
        }, 
        "brief_summary": {
            "textblock": "Phase II study of cetuximab, paclitaxel, carboplatin and radiation for esophageal cancer."
        }, 
        "brief_title": "Cetuximab, Paclitaxel, Carboplatin And Radiation For Esophageal, Gastroesophageal Junction And Gastric Cancer", 
        "completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Esophageal Cancer", 
            "Gastric Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Esophageal Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Cetuximab, paclitaxel, carboplatin weekly for 6 weeks with 50.4 Gy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  nonmetastatic esophageal or gastric cancer\n\n        Exclusion Criteria:\n\n        metastatic disease -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904435", 
            "org_study_id": "BrUOG 203", 
            "secondary_id": [
                "Kayla Rosati", 
                "401-863-3000"
            ]
        }, 
        "intervention": {
            "arm_group_label": "chemotherapy/radiation", 
            "intervention_name": "Chemotherapy/Radiation", 
            "intervention_type": "Drug", 
            "other_name": "Cetuximab, paclitaxel, carboplatin and radiation then surgery"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cetuximab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "cetuximab", 
            "gastric cancer", 
            "esophageal cancer"
        ], 
        "lastchanged_date": "July 17, 2013", 
        "number_of_arms": "1", 
        "official_title": "BrUOG-E/G-203 CETUXIMAB, PACLITAXEL, CARBOPLATIN AND RADIATION FOR ESOPHAGEAL, GASTROESOPHAGEAL JUNCTION AND GASTRIC CANCER", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "pathology used for assessment", 
            "measure": "Number of patients with clinical complete response change from treatment to follow-up", 
            "safety_issue": "No", 
            "time_frame": "completion of chemo/radiation and 6 months post drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904435"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brown University", 
            "investigator_full_name": "howard safran", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients with toxicity throughout study treatment", 
            "safety_issue": "Yes", 
            "time_frame": "weekly during chemo/radiation and at completion of chemo/radiation and during follow-up for surivival (maximum of 5 years)"
        }, 
        "source": "Brown University", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Brown University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2005", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}